{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:06:15Z","timestamp":1793736375469,"version":"4.6.1"},"reference-count":346,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.antiviral.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T21:47:41Z","timestamp":1523310461000},"page":"66-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":533,"special_numbering":"C","title":["The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0154-3459","authenticated-orcid":false,"given":"Katherine L.","family":"Seley-Radtke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.04.004_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1073\/pnas.52.2.493","article-title":"Biological and biochemical properties of the analogue antibiotic tubercidin","volume":"52","author":"Acs","year":"1964","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.004_bib2","doi-asserted-by":"crossref","first-page":"10611","DOI":"10.1016\/S0040-4020(01)89258-9","article-title":"Synthesis of carbocyclic nucleosides","volume":"50","author":"Agrofoglio","year":"1994","journal-title":"Tetrahedron"},{"key":"10.1016\/j.antiviral.2018.04.004_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2006.11.002","article-title":"Synthesis and antiviral activity of C-fluoro-branched cyclopropyl nucleosides","volume":"42","author":"Aihong","year":"2007","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib4","first-page":"695","article-title":"Conformational analysis, molecular structure and solid state simulation of the antiviral drug acyclovir (zovirax) using density functional theory methods","volume":"7","author":"Alvarez-Ros","year":"2014","journal-title":"Pharm. Basel"},{"key":"10.1016\/j.antiviral.2018.04.004_bib5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jac\/44.2.151","article-title":"Current and future antifungal therapy: new targets for antifungal agents","volume":"44","author":"Andriole","year":"1999","journal-title":"J Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.04.004_bib8","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/jm00120a010","article-title":"Synthesis and antiherpetic activity of (+\/-)-9- (Z)-2-(hydroxymethyl)cyclopropyl methyl guanine and related compounds","volume":"31","author":"Ashton","year":"1988","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2018.04.004_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0166-3542(02)00129-8","article-title":"Z-isomers of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and guanine (synguanol) are active against ganciclovir- and foscarnet-resistant human cytomegalovirus UL97 mutants","volume":"56","author":"Baldanti","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/bbrc.1998.9298","article-title":"Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir","volume":"250","author":"Balimane","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2018.04.004_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkf037","article-title":"Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication","volume":"50","author":"Balzarini","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)\u2013a novel potent and orally active immunosuppressive agent","volume":"1","author":"Bantia","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/095632020101200405","article-title":"Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues","volume":"12","author":"Barnard","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1021\/jm0493966","article-title":"Synthesis and antiviral evaluation of cis-substituted cyclohexenyl and cyclohexanyl nucleosides","volume":"48","author":"Barral","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib16","first-page":"416","article-title":"Gemcitabine and glioblastoma: challenges and current perspectives","volume":"2","author":"Bastiancich","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2018.04.004_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/oxfordjournals.bmb.a072069","article-title":"A history of the discovery and clinical application of antiviral drugs","volume":"41","author":"Bauer","year":"1985","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.antiviral.2018.04.004_bib18","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1038\/ncomms7903","article-title":"Direct synthesis of imino-C-nucleoside analogues and other biologically active iminosugars","volume":"6","author":"Bergeron-Brlek","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2018.04.004_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s10637-009-9377-7","article-title":"Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models","volume":"29","author":"Bergman","year":"2011","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.antiviral.2018.04.004_bib20","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/jo01128a007","article-title":"Contributions to the study of marine products. Xxxix. The nucleosides of sponges. Iii.1 spongothymidine and Spongouridine2","volume":"20","author":"Bergmann","year":"1955","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib21","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1021\/ja01162a543","article-title":"The isolation of a new thymine pentoside from Sponges1","volume":"72","author":"Bergmann","year":"1950","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1021\/jo01146a023","article-title":"Contributions to the study of marine products. Xxxii. The nucleosides of sponges. I.1","volume":"16","author":"Bergmann","year":"1951","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-3542(95)00066-6","article-title":"Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy","volume":"28","author":"Beutner","year":"1995","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/jm00142a009","article-title":"Pyrazolopyrimidine nucleosides. 12. Synthesis and biological activity of certain pyrazolo[3,4-d]pyrimidine nucleosides related to adenosine","volume":"24","author":"Bhat","year":"1981","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0960-894X(96)00594-X","article-title":"BMS-200475, a novel carbocyclic 2\u2032-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro","volume":"7","author":"Bisacchi","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0005-2787(67)90581-3","article-title":"On the mode of action of 7-deaza-adenosine (tubercidin)","volume":"138","author":"Bloch","year":"1967","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2018.04.004_bib28","first-page":"59","article-title":"Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults","volume":"53","author":"Bodey","year":"1969","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.antiviral.2018.04.004_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"Bohm","year":"2004","journal-title":"Chembiochem"},{"key":"10.1016\/j.antiviral.2018.04.004_bib30","series-title":"Chemical Synthesis of Nucleoside Analogues","article-title":"Synthesis of C-Nucleosides","author":"Boutureira","year":"2013"},{"key":"10.1016\/j.antiviral.2018.04.004_bib31","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1128\/AAC.31.8.1238","article-title":"Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture","volume":"31","author":"Boyd","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/095632029300401S01","article-title":"Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern","volume":"4","author":"Boyd","year":"1993","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib33","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1371\/journal.ppat.0020010","article-title":"Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?","volume":"2","author":"Boyer","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.04.004_bib34","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1021\/jm801176e","article-title":"The nucleoside analogue D-carba T blocks HIV-1 reverse transcription","volume":"52","author":"Boyer","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib35","first-page":"207","article-title":"Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection","volume":"8","author":"Bras","year":"2001","journal-title":"Can. J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.carres.2014.01.024","article-title":"The synthesis of gemcitabine","volume":"387","author":"Brown","year":"2014","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.carres.2015.01.001","article-title":"A linear synthesis of gemcitabine","volume":"406","author":"Brown","year":"2015","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.45.1.229-235.2001","article-title":"Antiviral L-nucleosides specific for hepatitis B virus infection","volume":"45","author":"Bryant","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1081\/NCN-100002336","article-title":"Anti-HBV specific beta-L-2'-deoxynucleosides","volume":"20","author":"Bryant","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.04.004_bib40","doi-asserted-by":"crossref","first-page":"15827","DOI":"10.1074\/jbc.270.26.15827","article-title":"Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir","volume":"270","author":"Burnette","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1135\/cccc20061088","article-title":"Purine and pyrimidine nucleoside analogs of 3'-C-methyladenosine as antitumor agents","volume":"71","author":"Cappellacci","year":"2006","journal-title":"Collect Czechoslov Chem. Comm."},{"key":"10.1016\/j.antiviral.2018.04.004_bib42","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1128\/AAC.34.6.1297","article-title":"Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro","volume":"34","author":"Carter","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib43","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1600-6143.2008.02220.x","article-title":"Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients","volume":"8","author":"Chamberlain","year":"2008","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.antiviral.2018.04.004_bib44","doi-asserted-by":"crossref","first-page":"13938","DOI":"10.1016\/S0021-9258(19)49660-9","article-title":"Deoxycytidine deaminase-resistant stereoisomer is the active form of (+\/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication","volume":"267","author":"Chang","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib45","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.3390\/molecules19033149","article-title":"5-azacytidine induces anoikis, inhibits mammosphere formation and reduces metalloproteinase 9 activity in MCF-7 human breast cancer cells","volume":"19","author":"Chang","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2018.04.004_bib46","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","article-title":"Tenofovir disoproxil fumarate","volume":"63","author":"Chapman","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.04.004_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/152165400410182","article-title":"Pseudouridine in RNA: what, where, how, and why","volume":"49","author":"Charette","year":"2000","journal-title":"IUBMB Life"},{"key":"10.1016\/j.antiviral.2018.04.004_bib48","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.bmcl.2015.07.086","article-title":"Thiophene-expanded guanosine analogues of Gemcitabine","volume":"25","author":"Chen","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib49","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1021\/jm030116g","article-title":"A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude","volume":"46","author":"Choi","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib50","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.39.4.979","article-title":"Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus","volume":"39","author":"Chu","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib51","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/jm00358a029","article-title":"Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]","volume":"26","author":"Colla","year":"1983","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib52","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-119-8-199310150-00003","article-title":"Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection","volume":"119","author":"Collier","year":"1993","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib53","first-page":"255","article-title":"How SCN anomeric effects and energetic preference across [SCCO] fragments steer conformational equilibria in 4'-thionucleosides. 1 H NMR and ab initio MO study","volume":"2","author":"Crnugelj","year":"2002","journal-title":"J. Chem. Soc. Perkin Trans. 2 Phys. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib55","volume":"61","author":"Curran","year":"2001","journal-title":"Valganciclovir. Drugs"},{"key":"10.1016\/j.antiviral.2018.04.004_bib56","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.41.5.1082","article-title":"1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity","volume":"41","author":"Daluge","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib57","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2165\/00003495-200363200-00007","article-title":"Adefovir dipivoxil: a review of its use in chronic hepatitis B","volume":"63","author":"Dando","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.04.004_bib58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1073\/pnas.57.3.548","article-title":"The structure of showdomycin, a novel carbon-linked nucleoside antibiotic related to uridine","volume":"57","author":"Darnall","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.004_bib59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/15257770.2014.917671","article-title":"The 5'-nor aristeromycin analogues of 5'-deoxy-5'-methylthioadenosine and 5'-deoxy-5'-thiophenyladenosine","volume":"33","author":"Das","year":"2014","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.04.004_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj2050001","article-title":"Specific targets for antiviral drugs","volume":"205","author":"De Clercq","year":"1982","journal-title":"Biochem. J."},{"key":"10.1016\/j.antiviral.2018.04.004_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1128\/AAC.28.1.84","article-title":"Antiviral and antimetabolic activities of neplanocins","volume":"28","author":"De Clercq","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs","volume":"1","author":"De Clercq","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2018.04.004_bib63","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","author":"De Clercq","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.04.004_bib64","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","author":"De Clercq","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib65","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.mib.2005.08.010","article-title":"Recent highlights in the development of new antiviral drugs","volume":"8","author":"De Clercq","year":"2005","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2005.05.001","article-title":"Antiviral drug discovery and development: where chemistry meets with biomedicine","volume":"67","author":"De Clercq","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib67","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.bcp.2006.09.014","article-title":"Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge","volume":"73","author":"De Clercq","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2006.10.006","article-title":"The acyclic nucleoside phosphonates from inception to clinical use: historical perspective","volume":"75","author":"De Clercq","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib69","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.624","article-title":"The history of antiretrovirals: key discoveries over the past 25 years","volume":"19","author":"De Clercq","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.antiviral.2018.04.004_bib71","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3390\/v2061322","article-title":"Historical perspectives in the development of antiviral agents against poxviruses","volume":"2","author":"De Clercq","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.04.004_bib72","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.apsb.2012.10.001","article-title":"Milestones in the discovery of antiviral agents: nucleosides and nucleotides","volume":"2","author":"De Clercq","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.antiviral.2018.04.004_bib73","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-405880-4.00009-3","article-title":"Antiviral agents","volume":"67","author":"De Clercq","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP2533","article-title":"Selective anti-herpesvirus agents","volume":"23","author":"De Clercq","year":"2013","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib76","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1021\/acs.jmedchem.5b01157","article-title":"C-nucleosides to Be revisited","volume":"59","author":"De Clercq","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"De Clercq","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib78","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2018.04.004_bib79","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.04.004_bib80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-540-79086-0_3","article-title":"Antiviral agents acting as DNA or RNA chain terminators","author":"De Clercq","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib81","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1073\/pnas.76.6.2947","article-title":"(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent","volume":"76","author":"De Clercq","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.004_bib82","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/AAC.33.8.1291","article-title":"Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives","volume":"33","author":"De Clercq","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib83","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1081\/NCN-100002298","article-title":"Acyclic\/carbocyclic guanosine analogues as anti-herpesvirus agents","volume":"20","author":"De Clercq","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.04.004_bib84","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1081\/NCN-200059772","article-title":"Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines","volume":"24","author":"De Clercq","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"Suppl. B","key":"10.1016\/j.antiviral.2018.04.004_bib85","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/12.suppl_B.29","article-title":"Pharmacokinetics of acyclovir after intravenous and oral administration","volume":"12","author":"de Miranda","year":"1983","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib86","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib87","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0022-3565(24)37707-9","article-title":"Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2","volume":"286","author":"de Vrueh","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.antiviral.2018.04.004_bib88","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0924-8579(94)90024-8","article-title":"Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients","volume":"4","author":"Degreef","year":"1994","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.antiviral.2018.04.004_bib89","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00003495-200969020-00002","article-title":"Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides","volume":"69","author":"Deval","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.04.004_bib90","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/AAC.00186-07","article-title":"Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase","volume":"51","author":"Deval","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib91","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1021\/ja01417a035","article-title":"The preparation of the acyl and alkyl derivatives of resorcinol","volume":"48","author":"Dohme","year":"1926","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib92","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1073\/pnas.88.19.8495","article-title":"Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues","volume":"88","author":"Doong","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.004_bib93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/15257779908043066","article-title":"A practical synthesis of L-FMAU from L-arabinose","volume":"18","author":"Du","year":"1999","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.04.004_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmre.2001.2314","article-title":"Dependence of 13C NMR chemical shifts on conformations of rna nucleosides and nucleotides","volume":"150","author":"Ebrahimi","year":"2001","journal-title":"J. Magn. Reson"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2018.04.004_bib95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jmv.1890410503","article-title":"Acyclovir: discovery, mechanism of action, and selectivity","author":"Elion","year":"1993","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib96","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.004_bib97","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/15257779908043065","article-title":"Kinetics for the acid-catalyzed hydrolysis of purine and cytosine 2\u2032-Deoxy-4\u2032-thionucleosides","volume":"18","author":"Elzagheid","year":"1999","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.04.004_bib98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1021\/cr60307a003","article-title":"Phosphonates as analogues of natural phosphates","volume":"77","author":"Engel","year":"1977","journal-title":"Chem. Rev."},{"key":"10.1016\/j.antiviral.2018.04.004_bib99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2017.03.012","article-title":"Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses","volume":"142","author":"Eyer","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib100","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/AAC.41.5.1099","article-title":"Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89","volume":"41","author":"Faletto","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2710.1989.tb00256.x","article-title":"Ganciclovir\u2013a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections","volume":"14","author":"Fan-Havard","year":"1989","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.antiviral.2018.04.004_bib102","first-page":"58","article-title":"Antiviral drugs - a short history of their discovery and development","volume":"31","author":"Field","year":"2004","journal-title":"Microbiol. Today"},{"key":"10.1016\/j.antiviral.2018.04.004_bib103","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/jm048944c","article-title":"Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors","volume":"48","author":"Franchetti","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02789061","article-title":"Acyclic nucleosides as antiviral compounds","volume":"5","author":"Freeman","year":"1996","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib105","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0149-2918(02)80058-3","article-title":"Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection","volume":"24","author":"Fung","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.antiviral.2018.04.004_bib106","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0005-2787(66)90120-1","article-title":"Biological activities of 3-isoadenosine","volume":"119","author":"Gerzon","year":"1966","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2018.04.004_bib107","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.2001.19.3.762","article-title":"Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia","volume":"19","author":"Giles","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib108","series-title":"Chemical Synthesis of Nucleoside Analogues","first-page":"605","article-title":"Uncommon three-, four-, and six-membered nucleosides","author":"Groaz","year":"2013"},{"key":"10.1016\/j.antiviral.2018.04.004_bib109","first-page":"4187","article-title":"Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells","volume":"56","author":"Grove","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib110","first-page":"3008","article-title":"Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration","volume":"55","author":"Grove","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib111","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(02)00028-0","article-title":"Treatment of myelodysplastic syndromes with 5-azacytidine","volume":"26","author":"Gryn","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib112","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/AAC.38.2.275","article-title":"Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine","volume":"38","author":"Gu","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib113","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1021\/jm990219s","article-title":"Synthesis of fluorosugar analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole as antivirals with potentially increased glycosidic bond stability","volume":"43","author":"Gudmundsson","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib114","first-page":"9","article-title":"L-Nucleosides as chemotherapeutic agents","volume":"202","author":"Gumina","year":"2001","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib115","series-title":"Deoxynucleoside Analogs in Cancer Therapy","first-page":"173","article-title":"L-nucleosides as chemotherapeutic agents","author":"Gumina","year":"2007"},{"key":"10.1016\/j.antiviral.2018.04.004_bib116","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib117","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2533\/chimia.2007.313","article-title":"Marine natural products. Key advances to the practical application of this resource in drug development","volume":"61","author":"Hamann","year":"2007","journal-title":"Chimia"},{"key":"10.1016\/j.antiviral.2018.04.004_bib118","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/13543784.14.4.511","article-title":"Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B","volume":"14","author":"Han","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2018.04.004_bib119","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1016\/S0040-4039(00)99010-5","article-title":"An improved synthesis of the antiviral acyclonucleoside 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine","volume":"26","author":"Harnden","year":"1985","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib120","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/jm00128a012","article-title":"Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties","volume":"32","author":"Harnden","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib121","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/315317","article-title":"Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group","volume":"181","author":"Harrigan","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.004_bib122","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.31.11.1849","article-title":"9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity","volume":"31","author":"Hasobe","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib123","first-page":"s65","article-title":"Structures of neplanocins, new antitumor antibiotics","author":"Hayashi","year":"1980","journal-title":"Nucleic Acids Symp. Ser."},{"key":"10.1016\/j.antiviral.2018.04.004_bib124","doi-asserted-by":"crossref","first-page":"675","DOI":"10.7164\/antibiotics.34.675","article-title":"Studies on neplanocin A, new antitumor antibiotic. II. Structure determination","volume":"34","author":"Hayashi","year":"1981","journal-title":"J. Antibiot. Tokyo"},{"key":"10.1016\/j.antiviral.2018.04.004_bib125","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1128\/AAC.34.2.287","article-title":"Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro","volume":"34","author":"Hayashi","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib126","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/07328319908044851","article-title":"The synthesis of carbocyclic 5\u2032-nor thymidine and an isomer as oligonucleotide monomers","volume":"18","author":"Hegde","year":"1999","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.04.004_bib127","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/15257770008033008","article-title":"Carbocyclic 5'-noruridine","volume":"19","author":"Hegde","year":"2000","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.04.004_bib128","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0960-894X(01)00270-0","article-title":"The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides","volume":"11","author":"Herdewijn","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib129","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s002800100370","article-title":"Gemcitabine activity in cervical cancer cell lines","volume":"48","author":"Hern\u00e1ndez","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib130","first-page":"4417","article-title":"Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine)","volume":"50","author":"Hertel","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib131","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V62.2.361.361","article-title":"High-dose cytosine arabinoside therapy for refractory leukemia","volume":"62","author":"Herzig","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2018.04.004_bib132","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.coph.2004.06.004","article-title":"Antivirals against DNA viruses (hepatitis B and the herpes viruses)","volume":"4","author":"Hewlett","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib133","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF01702925","article-title":"Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens","volume":"62","author":"Hiddemann","year":"1991","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib134","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.antiviral.2006.06.002","article-title":"Antiviral acyclic nucleoside phosphonates structure activity studies","volume":"71","author":"Hol\u00fd","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib135","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1135\/cccc19872801","article-title":"Acyclic nucleotide analogs .3. Synthesis of 9-(2-Phosphonylmethoxyethyl)Adenine and related-compounds","volume":"52","author":"H\u00f3ly","year":"1987","journal-title":"Collect Czechoslov Chem. Comm."},{"key":"10.1016\/j.antiviral.2018.04.004_bib136","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/jo01030a546","article-title":"Nucleosides. V. The monomesylates of 1-(2'-Deoxy-\u03b2-D-lyxofuranosyl)thymine","volume":"29","author":"Horwitz","year":"1964","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib137","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/jo01339a045","article-title":"Nucleosides. IX. The formation of 2',2'-unsaturated pyrimidine nucleosides via a novel beta-elimination reaction","volume":"31","author":"Horwitz","year":"1966","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib138","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jo01278a070","article-title":"Nucleosides. XI. 2',3'-dideoxycytidine","volume":"32","author":"Horwitz","year":"1967","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib139","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1128\/AAC.38.12.2792","article-title":"Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice","volume":"38","author":"Hostetler","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib140","first-page":"6110","article-title":"Action of 2',2'-difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib141","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1126\/science.282.5394.1669","article-title":"Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance","volume":"282","author":"Huang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.04.004_bib142","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1212\/WNL.35.10.1475","article-title":"Central nervous system toxicity with high-dose Ara-C","volume":"35","author":"Hwang","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.antiviral.2018.04.004_bib143","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/nar\/26.9.2237","article-title":"The effect of two antipodal fluorine-induced sugar puckers on the conformation and stability of the Dickerson-Drew dodecamer duplex [d(CGCGAATTCGCG)]2","volume":"26","author":"Ikeda","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib144","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/jo051248f","article-title":"Practical synthesis of 2'-deoxy-4'-thioribonucleosides: substrates for the synthesis of 4'-thioDNA","volume":"70","author":"Inoue","year":"2005","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib145","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.7164\/antibiotics.41.1711","article-title":"Nucleoside antibiotics: structure, biological activity, and biosynthesis","volume":"41","author":"Isono","year":"1988","journal-title":"J. Antibiot. Tokyo"},{"key":"10.1016\/j.antiviral.2018.04.004_bib146","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jhet.5570090301","article-title":"Synthetic studies of potential antimetabolites. XIII. Synthesis of 7-amino-3-\u03b2-d-ribofuranosyl-3H-imidazo 4,5-b pyridine (1-deazaadenosine) and related nucleosides","volume":"9","author":"Itoh","year":"1972","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib147","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003495-199958010-00015","article-title":"Lamivudine. A review of its therapeutic potential in chronic hepatitis B","volume":"58","author":"Jarvis","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.04.004_bib148","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2018.04.004_bib149","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib151","first-page":"4803","article-title":"Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models","volume":"57","author":"Kadhim","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib152","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/07328319008045135","article-title":"Crystal and molecular structure of (+)-Carba-Thymidine, C11 H10 N2 O6","volume":"9","author":"K\u00e1lm\u00e1n","year":"1989","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.04.004_bib153","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2307\/3283453","article-title":"Antitrypanosomal activity of phosphonylmethoxyalkylpurines","volume":"80","author":"Kaminsky","year":"1994","journal-title":"J. Parasitol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib154","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-3156.1996.tb00036.x","article-title":"(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]: a purine analogue with trypanocidal activity in vitro and in vivo","volume":"1","author":"Kaminsky","year":"1996","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.antiviral.2018.04.004_bib155","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1126\/science.145.3632.585","article-title":"Therapeutic antiviral action of 5-trifluoromethyl-2'-deoxyuridine in herpes simplex keratitis","volume":"145","author":"Kaufman","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.04.004_bib156","doi-asserted-by":"crossref","first-page":"14064","DOI":"10.1021\/bi9713862","article-title":"Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance","volume":"36","author":"Kerr","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.04.004_bib157","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1073\/pnas.071050798","article-title":"Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes","volume":"98","author":"Kicska","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.004_bib158","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1021\/jm00089a007","article-title":"Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity","volume":"35","author":"Kim","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib159","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1016\/S0040-4039(00)60890-0","article-title":"Potent anti-HIV and anti-HBV activities of (\u2212)-L-\u03b2-dioxolane-C and (+)-L-\u03b2-dioxolane-T and their asymmetric syntheses","volume":"33","author":"Kim","year":"1992","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1021\/jm00053a004","article-title":"1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes","volume":"36","author":"Kim","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib161","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1345\/aph.1G027","article-title":"Telbivudine: a novel nucleoside analog for chronic hepatitis B","volume":"40","author":"Kim","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib162","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/spid.2001.24097","article-title":"Acyclovir derivatives and other new antiviral agents","volume":"12","author":"Kimberlin","year":"2001","journal-title":"Semin. Pediatr. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.004_bib163","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0190-9622(88)70022-5","article-title":"History, pharmacokinetics, and pharmacology of acyclovir","volume":"18","author":"King","year":"1988","journal-title":"J. Am. Acad. Dermatol"},{"key":"10.1016\/j.antiviral.2018.04.004_bib164","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jfluchem.2006.06.007","article-title":"Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules","volume":"127","author":"Kirk","year":"2006","journal-title":"J. Fluor. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.10.011","article-title":"Resistance of human cytomegalovirus to ganciclovir\/valganciclovir: a comprehensive review of putative resistance pathways","volume":"101","author":"Komatsu","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib166","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2174\/138955707781662636","article-title":"Forodesine (BCX-1777, Immucillin H)\u2013a new purine nucleoside analogue: mechanism of action and potential clinical application","volume":"7","author":"Korycka","year":"2007","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib167","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/ar068200o","article-title":"Synthesis and properties of size-expanded DNAs: toward designed, functional genetic systems","volume":"40","author":"Krueger","year":"2007","journal-title":"Acc. Chem. Res."},{"issue":"Pt 3","key":"10.1016\/j.antiviral.2018.04.004_bib168","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1107\/S0108270187011144","article-title":"Structure of 3-isoadenosine","volume":"44","author":"Kumar","year":"1988","journal-title":"Acta Crystallogr. C"},{"key":"10.1016\/j.antiviral.2018.04.004_bib169","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.04.004_bib170","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib171","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib172","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1128\/JVI.02395-06","article-title":"Inhibition of hepatitis B virus polymerase by entecavir","volume":"81","author":"Langley","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib173","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.molcatb.2016.08.015","article-title":"New developments in nucleoside analogues biosynthesis: a review","volume":"133","author":"Lapponi","year":"2016","journal-title":"J. Mol. Catal. B Enzym."},{"key":"10.1016\/j.antiviral.2018.04.004_bib174","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.2479983","article-title":"Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)","volume":"246","author":"Larder","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.04.004_bib175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/365451a0","article-title":"Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro","volume":"365","author":"Larder","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.04.004_bib176","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/AAC.6.5.598","article-title":"Assessment of cytosine arabinoside as an antiviral agent in humans","volume":"6","author":"Lauter","year":"1974","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib177","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1021\/ja0619004","article-title":"Exploring the limits of DNA size: naphtho-homologated DNA bases and pairs","volume":"128","author":"Lee","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib178","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1021\/ja01495a070","article-title":"Potential anticancer agents. XL. Synthesis of the banomer of 9-(d-arabinofuranosyl)-adenine","volume":"82","author":"Lee","year":"1960","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib179","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1021\/ja01495a070","article-title":"Potential anticancer Agents.1 Xl. Synthesis of the \u03b2-anomer of 9-(d-arabinofuranosyl)-adenine","volume":"82","author":"Lee","year":"1960","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib180","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-05-2249","article-title":"Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue","volume":"12","author":"Lee","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib181","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/ar00077a001","article-title":"Dimensional probes of enzyme-coenzyme binding-sites","volume":"15","author":"Leonard","year":"1982","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib182","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/ja00896a036","article-title":"The synthesis of 3-\u03b2-D-Ribofuranosyladenine","volume":"85","author":"Leonard","year":"1963","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib183","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1021\/bi00878a027","article-title":"Synthesis of 3-\u03b2-D-Ribofuranosyladenine and (3-\u03b2-d-ribofuranosyladenine)-5'-phosphate*","volume":"4","author":"Leonard","year":"1965","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.04.004_bib184","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1021\/jo00891a021","article-title":"Linear benzoadenine. A stretched-out analog of adenine","volume":"40","author":"Leonard","year":"1975","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib185","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1021\/ja00429a040","article-title":"Defined dimensional changes in enzyme substrates and cofactors. Synthesis of lin-benzoadenosine and enzymatic evaluation of derivatives of the benzopurines","volume":"98","author":"Leonard","year":"1976","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib186","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/bi00611a001","article-title":"Dimensional probes of the enzyme binding sites of adenine nucleotides. Biological effects of widening the adenine ring by 2.4 A","volume":"17","author":"Leonard","year":"1978","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.04.004_bib187","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1749-6632.1986.tb48041.x","article-title":"Relatives of Watson-Crick DNA, RNA cross sections","volume":"471","author":"Leonard","year":"1986","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.antiviral.2018.04.004_bib188","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0960-894X(97)10178-0","article-title":"Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent","volume":"8","author":"Li","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib189","doi-asserted-by":"crossref","DOI":"10.1021\/acs.accounts.6b00274","article-title":"Discovery and development of the anti-human immunodeficiency virus drug, emtricitabine (emtriva, FTC)","author":"Liotta","year":"2016","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib190","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1081\/NCN-100108327","article-title":"Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor\/antiviral agents","volume":"20","author":"Liu","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.04.004_bib191","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jfluchem.2008.06.007","article-title":"Fluorinated nucleosides: synthesis and biological implication","volume":"129","author":"Liu","year":"2008","journal-title":"J. Fluor Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib192","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.antiviral.2018.04.004_bib193","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1016\/j.bmcl.2005.05.071","article-title":"Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain","volume":"15","author":"Luoni","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib194","doi-asserted-by":"crossref","first-page":"14704","DOI":"10.1021\/ja065606n","article-title":"Toward a designed, functioning genetic system with expanded-size base pairs: solution structure of the eight-base xDNA double helix","volume":"128","author":"Lynch","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib195","series-title":"Therapy of Viral Infections","first-page":"53","article-title":"Phosphonated nucleoside analogues as antiviral agents","author":"Macchi","year":"2015"},{"key":"10.1016\/j.antiviral.2018.04.004_bib196","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cell.2017.05.042","article-title":"Antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase","volume":"169","author":"Maffioli","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2018.04.004_bib197","doi-asserted-by":"crossref","first-page":"11046","DOI":"10.1002\/chem.201200733","article-title":"Stereoselective synthesis of D- and L-carbocyclic nucleosides by enzymatically catalyzed kinetic resolution","volume":"18","author":"Mahler","year":"2012","journal-title":"Chemistry"},{"key":"10.1016\/j.antiviral.2018.04.004_bib198","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1075-8593(96)80104-3","article-title":"Carbocyclic nucleosides","volume":"2","author":"Marquez","year":"1996","journal-title":"Adv. Antivir. Drug Des."},{"key":"10.1016\/j.antiviral.2018.04.004_bib199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.2610060102","article-title":"Carbocyclic nucleosides","volume":"6","author":"Marquez","year":"1986","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.antiviral.2018.04.004_bib200","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1021\/jm960306+","article-title":"Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides?","volume":"39","author":"Marquez","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib201","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jps.2600760221","article-title":"Synthesis and antiviral activity of various esters of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine","volume":"76","author":"Martin","year":"1987","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.antiviral.2018.04.004_bib202","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa011759","article-title":"A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis","volume":"346","author":"Martin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib203","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2009.10.006","article-title":"Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides","volume":"85","author":"Martin","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib204","first-page":"9","article-title":"Looking past two drugs, looking past three?","volume":"3","author":"Mascolini","year":"1997","journal-title":"J. Int. Assoc. Physicians AIDS Care"},{"key":"10.1016\/j.antiviral.2018.04.004_bib205","series-title":"Immunologic Markers to Evaluate Immune-based Therapies in HIV Disease Meeting Report","author":"Mascolini","year":"2010"},{"key":"10.1016\/j.antiviral.2018.04.004_bib206","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.antiviral.2006.04.017","article-title":"L-nucleoside enantiomers as antivirals drugs: a mini-review","volume":"71","author":"Math\u00e9","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib207","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1070\/RC2012v081n08ABEH004314","article-title":"Carbocyclic nucleoside analogues: classification, target enzymes, mechanisms of action and synthesis","volume":"81","author":"Matyugina","year":"2012","journal-title":"Russ. Chem. Rev."},{"key":"10.1016\/j.antiviral.2018.04.004_bib208","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archopht.1984.01040030118049","article-title":"Topical treatment of experimental herpes simplex keratouveitis with 2'-O-glycylacyclovir. A water-soluble ester of acyclovir","volume":"102","author":"Maudgal","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib209","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1021\/jm990346o","article-title":"Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base","volume":"42","author":"McGuigan","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib210","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir - effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib211","doi-asserted-by":"crossref","first-page":"31289","DOI":"10.1074\/jbc.C800188200","article-title":"The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation","volume":"283","author":"McMahon","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib212","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7326\/0003-4819-116-1-13","article-title":"Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase i\/ii study","volume":"116","author":"Meng","year":"1992","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib213","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archinte.1997.00440240109016","article-title":"Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group","volume":"157","author":"Mertz","year":"1997","journal-title":"Arch. Intern Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib214","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/15257779908041540","article-title":"Synthesis and biological activity of 4'-thio-2'-deoxy purine nucleosides","volume":"18","author":"Messini","year":"1999","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.04.004_bib215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(00)80185-9","article-title":"A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase","volume":"4","author":"Meyer","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2018.04.004_bib216","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1021\/jm00356a034","article-title":"Synthesis and antitumor activity of 2-deoxyribofuranosides of 3-deazaguanine","volume":"26","author":"Mian","year":"1983","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib217","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0008-6215(83)88357-8","article-title":"Synthesis and properties of 3\u2032-C-methylnucleosides and their phosphoric esters","volume":"124","author":"Mikhailov","year":"1983","journal-title":"Carb Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib218","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2',3'-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.004_bib219","first-page":"1775","article-title":"A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine","volume":"34","author":"Momparler","year":"1974","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib220","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1021\/jm00257a014","article-title":"Analogs of 5'-deoxy-5'-(methylthio)adenosine","volume":"17","author":"Montgomery","year":"1974","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib221","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1021\/jm00364a023","article-title":"Synthesis and biological evaluation of 2-fluoro-8-azaadenosine and related compounds","volume":"26","author":"Montgomery","year":"1983","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib222","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/AAC.39.5.1017","article-title":"Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry","volume":"39","author":"Nair","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib223","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1021\/ja00046a074","article-title":"Isodideoxynucleosides: a conceptually new class of nucleoside antiviral agents","volume":"114","author":"Nair","year":"1992","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib224","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.39.9.1993","article-title":"Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol","volume":"39","author":"Nair","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib225","first-page":"148","article-title":"Showdomycin, a new antibiotic from a Streptomyces SP","volume":"17","author":"Nishimura","year":"1964","journal-title":"J. Antibiot. Tokyo"},{"key":"10.1016\/j.antiviral.2018.04.004_bib226","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tim.2014.10.007","article-title":"Nucleoside antibiotics: biosynthesis, regulation, and biotechnology","volume":"23","author":"Niu","year":"2015","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib227","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1021\/jm00167a002","article-title":"Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS","volume":"33","author":"Norbeck","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib229","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ctrv.2014.07.003","article-title":"Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside","volume":"40","author":"Oettle","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.antiviral.2018.04.004_bib230","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.48.10.3944-3953.2004","article-title":"A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties","volume":"48","author":"Olsen","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib231","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bmcl.2017.01.040","article-title":"New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors","volume":"27","author":"Orlov","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib232","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0008-6215(00)00089-6","article-title":"Fluorinated nucleosides","volume":"327","author":"Pankiewicz","year":"2000","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib233","volume":"vol. 64","author":"Pankiewicz","year":"1993"},{"key":"10.1016\/j.antiviral.2018.04.004_bib234","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","article-title":"Metabolism of fluorine-containing drugs","volume":"41","author":"Park","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib235","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","article-title":"Metabolism of fluorine-containing drugs","volume":"41","author":"Park","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib236","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/AAC.37.5.1004","article-title":"Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism","volume":"37","author":"Parker","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib237","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1039\/b414739a","article-title":"The nucleoside transport proteins, NupC and NupG, from Escherichia coli: specific structural motifs necessary for the binding of ligands","volume":"3","author":"Patching","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib238","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1021\/jm00096a012","article-title":"The synthesis and antiviral properties of (.+-.)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design","volume":"35","author":"Patil","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib239","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/anie.196604951","article-title":"Carbohydrates containing nitrogen or sulfur in the \u201chemiacetal\u201d ring","volume":"5","author":"Paulsen","year":"1966","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.antiviral.2018.04.004_bib240","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.antiviral.2018.04.004_bib241","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/jhep.2001.20899","article-title":"Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)","volume":"33","author":"Peek","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.04.004_bib242","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/07328319208021748","article-title":"Nucleoside analogues as chemotherapeutic agents: a review","volume":"11","author":"Perigaud","year":"1992","journal-title":"Nucleoside Nucleotides"},{"key":"10.1016\/j.antiviral.2018.04.004_bib243","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2165\/00003495-199652050-00009","article-title":"Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections","volume":"52","author":"Perry","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.04.004_bib244","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3851\/IMP2012","article-title":"Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy","volume":"22","author":"Pertusati","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib245","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/QAD.0b013e32830b3ab5","article-title":"Efficacy and safety of entecavir for chronic HBV in HIV\/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy","volume":"22","author":"Pess\u00f4a","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2018.04.004_bib246","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/jm00146a007","article-title":"Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides","volume":"28","author":"Petrie","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib247","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1469-0691.2000.00014.x","article-title":"Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis","volume":"6","author":"Piketty","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2018.04.004_bib248","first-page":"1547","article-title":"Two approaches that increase the activity of analogs of adenine nucleosides in animal cells","volume":"35","author":"Plunkett","year":"1975","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib249","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/10529002013003007","article-title":"Tenofovir disoproxil fumarate (Viread)","volume":"13","author":"Porche","year":"2002","journal-title":"J. Assoc. Nurses AIDS Care"},{"key":"10.1016\/j.antiviral.2018.04.004_bib250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep.1840160103","article-title":"The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2'-deoxyguanosine","volume":"16","author":"Price","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.04.004_bib251","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-3002(59)90597-9","article-title":"Synthesis and biological activities of iododeoxyuridine, an analog of thymidine","volume":"32","author":"Prusoff","year":"1959","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2018.04.004_bib252","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm9705723","article-title":"(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity","volume":"41","author":"Qiu","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib253","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1021\/bi0503605","article-title":"Substrate discrimination by the human GTP fucose pyrophosphorylase","volume":"44","author":"Quirk","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.04.004_bib254","first-page":"3461","article-title":"Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo","volume":"58","author":"Rabbani","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib255","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/tcrm.2006.2.4.377","article-title":"Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes","volume":"2","author":"Raj","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.antiviral.2018.04.004_bib256","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.2174\/0929867322666150904144802","article-title":"Mechanism of adefovir, tenofovir and entecavir resistance: molecular modeling studies of how a novel anti-HBV agent (FMCA) can overcome the drug resistance","volume":"22","author":"Rawal","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib257","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.2174\/1568026616666160506145300","article-title":"Chemistry and bioactivities of aristeromycins: an overview","volume":"16","author":"Rawal","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib258","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib259","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1016\/S0021-9258(18)83248-3","article-title":"Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate","volume":"264","author":"Reardon","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib260","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11899-013-0156-3","article-title":"High-dose cytarabine (HD araC) in the treatment of leukemias: a review","volume":"8","author":"Reese","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.antiviral.2018.04.004_bib261","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.antiviral.2018.04.004_bib262","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1021\/jm00377a002","article-title":"Synthesis and antiviral\/antitumor activities of certain 3-deazaguanine nucleosides and nucleotides","volume":"27","author":"Revankar","year":"1984","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib263","first-page":"135","article-title":"Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus","volume":"7","author":"Richman","year":"1994","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.04.004_bib264","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1021\/jm00351a007","article-title":"Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 2. Synthesis and activity of some nucleosides of 4-(alkylamino)-1H-pyrazolo[3, 4-d]pyrimidines","volume":"25","author":"Rideout","year":"1982","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib265","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1389557033405331","article-title":"New progresses in the enantioselective synthesis and biological properties of carbocyclic nucleosides","volume":"3","author":"Rodr\u00edguez","year":"2003","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib266","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1021\/acs.chemrev.6b00174","article-title":"Recent trends in nucleotide synthesis","volume":"116","author":"Roy","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.antiviral.2018.04.004_bib267","first-page":"1605","article-title":"Showdomycin, a new nucleoside antibiotic","volume":"28","author":"Roy-Burman","year":"1968","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib268","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/1097-0142(197910)44:4<1189::AID-CNCR2820440404>3.0.CO;2-O","article-title":"High dose cytosine arabinoside (HDARAC) in refractory acute leukemia","volume":"44","author":"Rudnick","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.antiviral.2018.04.004_bib269","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1086\/498348","article-title":"Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus","volume":"42","author":"Saag","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.004_bib270","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jama.1996.03540010046029","article-title":"Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group","volume":"276","author":"Sacks","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2018.04.004_bib271","series-title":"Principles of Nucleic Acid Structure","first-page":"9","article-title":"Defining terms for the nucleic acids","author":"Saenger","year":"1984"},{"key":"10.1016\/j.antiviral.2018.04.004_bib272","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1021\/ol502899b","article-title":"Stereoselective synthesis of 4'-selenonucleosides via seleno-Michael reaction as potent antiviral agents","volume":"16","author":"Sahu","year":"2014","journal-title":"Org. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib273","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0022-2836(75)90213-2","article-title":"A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase","volume":"94","author":"Sanger","year":"1975","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib274","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.004_bib275","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1021\/bi00400a017","article-title":"Kinetics and thermodynamics of the interaction of 5-fluoro-2'-deoxyuridylate with thymidylate synthase","volume":"26","author":"Santi","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.04.004_bib276","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.sbi.2004.10.013","article-title":"Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases","volume":"14","author":"Sarafianos","year":"2004","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib277","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.1987.5.3.419","article-title":"Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma","volume":"5","author":"Schilsky","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib278","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/AAC.36.11.2423","article-title":"Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib279","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.36.3.672","article-title":"Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib280","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2174\/1568026033452465","article-title":"Imino-sugar-based nucleosides","volume":"3","author":"Schramm","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib281","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1021\/jm00149a033","article-title":"2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity","volume":"28","author":"Secrist","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib282","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1021\/jm9705869","article-title":"Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses","volume":"41","author":"Sekiyama","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib283","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/jm9605039","article-title":"(+)-7-Deaza-5\u2018-noraristeromycin as an anti-trypanosomal agent","volume":"40","author":"Seley","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib284","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1128\/AAC.41.8.1658","article-title":"Synthesis and antitrypanosomal activities of a series of 7-deaza-5'-noraristeromycin derivatives with variations in the cyclopentyl ring substituents","volume":"41","author":"Seley","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib285","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1021\/jo970515h","article-title":"A methylated derivative of 5\u2018-noraristeromycin","volume":"62","author":"Seley","year":"1997","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib286","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1080\/07328319708002560","article-title":"A 5\u2032-noraristeromycin enantiomer with activity towards hepatitis B virus","volume":"16","author":"Seley","year":"1997","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.04.004_bib287","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/jm9606148","article-title":"Synthesis and anti-trypanosomal activity of various 8-aza-7-deaza-5'noraristeromycin derivatives","volume":"40","author":"Seley","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib288","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0968-0896(98)00036-4","article-title":"The importance of the 4\u2032-hydroxyl hydrogen for the anti-trypanosomal and antiviral properties of (+)-5\u2032-Noraristeromycin and two 7-deaza analogues","volume":"6","author":"Seley","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib289","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1021\/jm000326i","article-title":"Synthesis and antitumor activity of thieno-separated tricyclic purines","volume":"43","author":"Seley","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib290","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1021\/ol035696q","article-title":"Carbocyclic isoadenosine analogues of neplanocin A","volume":"5","author":"Seley","year":"2003","journal-title":"Org. Lett."},{"key":"10.1016\/j.antiviral.2018.04.004_bib291","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/nass\/nrn321","article-title":"Hetero-expanded purine nucleosides. Design, synthesis and preliminary biological activity","author":"Seley-Radtke","year":"2008","journal-title":"Nucleic Acids Symp. Ser. Oxf"},{"key":"10.1016\/j.antiviral.2018.04.004_bib292","doi-asserted-by":"crossref","first-page":"9556","DOI":"10.1074\/jbc.272.14.9556","article-title":"Stereoisomers of deoxynucleoside 5'-triphosphates as substrates for template-dependent and -independent DNA polymerases","volume":"272","author":"Semizarov","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib293","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1021\/ja00968a055","article-title":"9- \u03b2-DL-2\u03b1,3\u03b1-Dihydroxy-4\u03b2-(hydroxymethyl)- cyclopentyl adenine, the Carbocyclic Analog of Adenosine1,2","volume":"88","author":"Shealy","year":"1966","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2018.04.004_bib294","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1128\/AAC.39.11.2555","article-title":"Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells","volume":"39","author":"Shirasaka","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib295","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/07328319308021205","article-title":"S-Adenosyl-L-homocysteine hydrolase inhibitors as anti-viral agents: 5\u2032-deoxyaristeromycin","volume":"12","author":"Siddiqi","year":"1992","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2018.04.004_bib296","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1021\/jm00006a023","article-title":"3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties","volume":"38","author":"Siddiqi","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib297","series-title":"The Organic Chemistry of Drug Design and Drug Action","first-page":"19","article-title":"Lead discovery and lead modification","author":"Silverman","year":"2014"},{"key":"10.1016\/j.antiviral.2018.04.004_bib298","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10126-004-0405-5","article-title":"Marine sponges as pharmacy","volume":"7","author":"Sipkema","year":"2005","journal-title":"Mar. Biotechnol. (NY)"},{"key":"10.1016\/j.antiviral.2018.04.004_bib299","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1023\/A:1008387019062","article-title":"Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units","volume":"9","author":"Siu","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib300","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib301","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.46.5.1329-1335.2002","article-title":"Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses","volume":"46","author":"Smee","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib302","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4757-9209-6_4","article-title":"Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster","volume":"394","author":"Smiley","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib303","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/AAC.01004-07","article-title":"Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro","volume":"52","author":"Smith","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib304","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.35.7.1386","article-title":"Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog","volume":"35","author":"Soudeyns","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib305","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","article-title":"Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans","volume":"39","author":"Soul-Lawton","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib306","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1126\/science.145.3632.548","article-title":"Enzymatic alteration of nucleic acid structure","volume":"145","author":"Srinivasan","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.04.004_bib307","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.1716788","article-title":"Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase","volume":"253","author":"St Clair","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.04.004_bib308","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/cr9002165","article-title":"C-nucleosides: synthetic strategies and biological applications","volume":"109","author":"Stambask\u00fd","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.antiviral.2018.04.004_bib309","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.44.1.207-209.2000","article-title":"Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy","volume":"44","author":"Steingrimsdottir","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-199005010-00003","article-title":"The toxicity of cytarabine","volume":"5","author":"Stentoft","year":"1990","journal-title":"Drug Saf."},{"key":"10.1016\/j.antiviral.2018.04.004_bib311","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/bi00542a016","article-title":"Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates","volume":"19","author":"Stoeckler","year":"1980","journal-title":"Biochem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib312","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2017.01.014","article-title":"Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures","volume":"140","author":"Stray","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib313","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.antiviral.2006.05.001","article-title":"Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus","volume":"72","author":"Suzuki","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib314","first-page":"51","article-title":"The discovery and development of a potent antiviral drug, entecavir, for the treatment of chronic hepatitis B","volume":"1","author":"Tang","year":"2013","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib315","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430-A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.antiviral.2018.04.004_bib316","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3762\/bjoc.14.65","article-title":"Recent advances in synthetic approaches to C-Nucleosides","volume":"14","author":"Temburnikar","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib317","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1128\/AAC.41.5.1094","article-title":"Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89","volume":"41","author":"Tisdale","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib318","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1016\/S0021-9258(17)43009-2","article-title":"Effects of acyclovir and its metabolites on purine nucleoside phosphorylase","volume":"259","author":"Tuttle","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib319","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-123-2-199507150-00002","article-title":"Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group","volume":"123","author":"Tyring","year":"1995","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.antiviral.2018.04.004_bib320","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/17415990802183876","article-title":"Lamivudine, an important drug in aids treatment","volume":"29","author":"Vasconcelos","year":"2008","journal-title":"J. Sulfur Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib321","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/095632029500600605","article-title":"Zalcitabine (DDC) phosphorylation and drug-interactions","volume":"6","author":"Veal","year":"1995","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib322","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/095632029300400201","article-title":"Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir","volume":"4","author":"Vere Hodge","year":"1993","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib323","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1128\/AAC.33.10.1765","article-title":"Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]","volume":"33","author":"Vere Hodge","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib324","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0006-291X(88)80950-1","article-title":"Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro","volume":"156","author":"Vince","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2018.04.004_bib325","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1081\/NCN-200027660","article-title":"Selective transport of a new class of purine antimetabolites by the protozoan parasite Trypanosoma brucei","volume":"23","author":"Wallace","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.04.004_bib326","first-page":"84","article-title":"Cyclisation during the phosphorylation of uridine and cytidine bypolyphosphoric acid-A new route to the O-2, 2\u2032-cyclonucleosides","volume":"3","author":"Walwick","year":"1959","journal-title":"Proc. Chem. Soc. Lond."},{"key":"10.1016\/j.antiviral.2018.04.004_bib327","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1021\/jo9908288","article-title":"Enantioselective synthesis and conformational study of cyclohexene carbocyclic nucleosides","volume":"64","author":"Wang","year":"1999","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib328","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/jm991171l","article-title":"The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine","volume":"43","author":"Wang","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib329","series-title":"Medicinal Chemistry of Nucleic Acids","first-page":"1","article-title":"Recent advances in carbocyclic nucleosides: synthesis and biological activity","author":"Wang","year":"2011"},{"key":"10.1016\/j.antiviral.2018.04.004_bib330","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.04.004_bib331","first-page":"69","article-title":"Anti-parasite activity of nucleoside analogues in Leishmania tropica promastigotes","author":"Wataya","year":"1984","journal-title":"Nucleic Acids Symp. Ser."},{"key":"10.1016\/j.antiviral.2018.04.004_bib332","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.bmc.2012.03.004","article-title":"Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues","volume":"20","author":"Wauchope","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib333","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.1993.196","article-title":"Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers","volume":"54","author":"Weller","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2018.04.004_bib334","first-page":"111","article-title":"Calculations of the conformational properties of acyclonucleosides. Part I. Stable conformations of acyclovir","volume":"34","author":"Weso\u0142owski","year":"1987","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.antiviral.2018.04.004_bib335","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/106002809603000911","article-title":"The past as prelude to the future: history, status, and future of antiviral drugs","volume":"30","author":"Whitley","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib228","unstructured":"WHO Model List of Essential Medicines. http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1."},{"key":"10.1016\/j.antiviral.2018.04.004_bib336","series-title":"Antiviral Drugs: from Basic Discovery through Clinical Trials","first-page":"401","article-title":"Discovery and development of entecavir","author":"Wilber","year":"2011"},{"key":"10.1016\/j.antiviral.2018.04.004_bib337","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/jo00827a045","article-title":"Direct glycosylation of 1,3,5-triazinones. A new approach to the synthesis of the nucleoside antibiotic 5-azacytidine (4-amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2-one) and related derivatives","volume":"35","author":"Winkley","year":"1970","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib338","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jfluchem.2012.06.026","article-title":"Synthesis and applications of fluorinated nucleoside analogues","volume":"143","author":"Wojtowicz-Rajchel","year":"2012","journal-title":"J. Fluor. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib339","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1021\/jm00109a001","article-title":"S-adenosyl-L-homocysteine hydrolase as a target for antiviral chemotherapy","volume":"34","author":"Wolfe","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.04.004_bib340","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1023\/A:1016234009624","article-title":"Pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats","volume":"12","author":"Wright","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.antiviral.2018.04.004_bib341","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1128\/AAC.33.2.171","article-title":"Pharmacokinetics and bioavailability of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus, in rats","volume":"33","author":"Yeom","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib342","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1002\/chem.201300741","article-title":"New RNA purine building blocks, 4'-selenopurine nucleosides: first synthesis and unusual mixture of sugar puckerings","volume":"19","author":"Yu","year":"2013","journal-title":"Chemistry"},{"key":"10.1016\/j.antiviral.2018.04.004_bib343","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200847060-00001","article-title":"A review of the pharmacokinetics of abacavir","volume":"47","author":"Yuen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2018.04.004_bib344","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1128\/AAC.38.2.282","article-title":"Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase","volume":"38","author":"Zhang","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.004_bib345","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1016\/j.tet.2008.09.011","article-title":"Mechanistic studies in the synthesis of a series of thieno-expanded xanthosine and guanosine nucleosides","volume":"64","author":"Zhang","year":"2008","journal-title":"Tetrahedron"},{"key":"10.1016\/j.antiviral.2018.04.004_bib346","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/15257770.2013.771187","article-title":"\u201cReverse\u201d carbocyclic fleximers: synthesis of a new class of adenosine deaminase inhibitors","volume":"32","author":"Zimmermann","year":"2013","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.04.004_bib347","doi-asserted-by":"crossref","first-page":"21200","DOI":"10.3390\/molecules191221200","article-title":"Design and synthesis of a series of truncated neplanocin fleximers","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Molecules"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218300500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218300500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:11Z","timestamp":1759062491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218300500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":346,"alternative-id":["S0166354218300500"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.004","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}